Related Experiment Videos
Glucocorticoid-induced osteoporosis: an update
Gherardo Mazziotti1, Alberto Angeli, John P Bilezikian
1Department of Internal Medicine, Spedali Civili, University of Brescia, 25125 Brescia, Italy.
Trends in Endocrinology and Metabolism: TEM
|May 9, 2006
Summary
Glucocorticoid-induced osteoporosis involves rapid bone loss and slower bone formation impairment. Bisphosphonates are the standard treatment, with new therapies under investigation.
Area of Science:
- Endocrinology
- Bone Biology
- Pharmacology
Background:
- Glucocorticoids induce osteoporosis via rapid early bone resorption and slower bone formation impairment.
- Direct effects on bone cells (osteoblasts, osteoclasts, osteocytes) are key to glucocorticoid-induced osteoporosis pathogenesis.
Purpose of the Study:
- To review the pathogenesis and management of glucocorticoid-induced osteoporosis.
- To highlight current and emerging therapeutic strategies.
Main Methods:
- Literature review of glucocorticoid-induced osteoporosis.
- Analysis of direct and indirect effects of glucocorticoids on bone metabolism.
- Evaluation of current and investigational treatments.
Main Results:
- Glucocorticoid-induced osteoporosis has two distinct phases: early resorption and later formation deficits.
- Management includes lifestyle adjustments, adequate calcium/vitamin D, and dose minimization.
- Bisphosphonates are the established first-line pharmacotherapy for postmenopausal women.
Conclusions:
- Early intervention with bisphosphonates is crucial for managing glucocorticoid-induced osteoporosis.
- Ongoing research focuses on anabolic and alternative therapies to address treatment gaps.